Edgen Stock·Sep 29 2025, 19:24戻る
戻る
Teva Pharmaceutical Secures FDA Fast Track Status for Emrusolmin in MSA Treatment
Edgen Stock·Sep 29 2025, 19:24
[1] Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin[2] Teva's Fast Track Designation for Emrusolmin in MSA: Strategic Pipeline Differentiation and Financial Recovery in a High-Risk Neurology Space - AInvest[3] Teva Pharmaceuticals' Emrusolmin Receives FDA Fast Track Designation for MSA Treatment Amidst Mixed Financial Health and Competitive Landscape - AInvest